RESEARCH

RESEARCH INTERESTS

mTOR is a serine/threonine kinase that coordinates anabolic and catabolic processes in the cell as a response to extracellular events such as nutrient levels, energy availability, or stress situations. mTOR and its signaling pathways have been described mainly in proliferative non-neuronal cells. Therefore, the role that mTOR plays in differentiated cells as neurons is not very clear. There is evidence of mTOR as a modulator of survival, differentiation, and development of neurons. It is also a key player in axonal growth, dendritic arborization, and synaptogenesis. In the adult brain, mTOR has been implicated in physiologic processes like neural plasticity, learning, or memory. Moreover, its activity can be altered in pathological processes including tuberous sclerosis, Alzheimer's disease, Parkinson's disease, brain tumors, and cortical dysplasia.

Our main research line is the study of mTOR and one of its main modulators, the protein RTP801/REDD1, in neurodegeneration associated with Parkinson's disease, Huntington's disease, Alzheimer's disease, neural plasticity, and development.

RESEARCH LINES

A novel role of RTP801 in Alzheimer's disease (AD) and inflammation


Our predoctoral student, Leticia Pérez-Sisqués, in collaboration with the group of Dr. Albert Giralt, investigated the role of RTP801 in AD pathology and inflammation. She found that neuronal RTP801  contributes to neuroinflammation and cognitive decline  in a murine AD mouse model. Right now we are investigating the crosstalk between neuron-glia to understand the mechanisms by which RTP801 mediates memory impairments and inflammation.

References:

1. Pérez-Sisqués L, Sancho-Balsells A, Solana-Balaguer J, Campoy-Campos G, Vives-Isern M, Soler-Palazón F, Anglada-Huguet M, López-Toledano MÁ, Mandelkow EM, Alberch J, Giralt A, Malagelada C. RTP801/REDD1 contributes to neuroinflammation severity and memory impairments in Alzheimer's disease. Cell Death Dis. 2021 Jun 15;12(6):616. doi: 10.1038/s41419-021-03899-y.


A novel role of RTP801 in Huntington's disease (HD)

Our predoctoral student, Núria Martín-Flores, in collaboration with the group of Dr. Esther Pérez-Navarro and Dr. Jordi Alberch found that RTP801 is up-regulated in HD human brains and in differentiating neurons derived from induced Pluripotent Stem Cells (iPSC) from HD patients. More importantly, in cellular models of HD, RTP801 mediated mutant huntingtin toxicity in neurons. In the R6/1 mouse model of HD, synaptic RTP801 contributed to motor-learning dysfunction. In the R6/1 mouse model, striatal RTP801 silencing normalized the Ser473 Akt hyperphosphorylation by downregulating Rictor and it induced synaptic elevation of calcium-permeable GluA1 subunit and TrkB receptor levels, suggesting an enhancement in synaptic plasticity.

References:

1. Martín-Flores N, Romani-Aumedes J, Rue L, et al. RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death. Mol Neurobiol. 2015. doi:10.1007/s12035-015-9166-6.

2. Martín-Flores N, Pérez-Sisqués L, Creus-Muncunill J, Masana M, Ginés S, Alberch J, Pérez-Navarro E, Malagelada C. Synaptic RTP801 contributes to motor-learning dysfunction in Huntington's disease. Cell Death Dis. 2020 Jul 30;11(7):569. doi: 10.1038/s41419-020-02775-5.


RTP801 regulation of mTOR signaling in Parkinson's disease (PD)

RTP801 is a stress-regulated protein that is sufficient and necessary to induce neuron death. It is elevated in cellular and animal models of PD in response to dopaminergic neurotoxins such as 6-Hydroxydopamine (6-OHDA) and MPP+/MPTP, and induces neuron death by a sequential inactivation of mTOR and the survival kinase Akt. Indeed, RTP801 is highly up-regulated in neuromelanin positive neurons in the SNpc of both sporadic and parkin mutant PD patients. Moreover, Rapamycin an inhibitor of most but not all mTOR activities was protective in cellular and animal models of PD by decreasing the levels of RTP801.  Hence, our main objective is to understand the role of RTP801 in neurodegeneration associated with PD. For this reason, we have been studying RTP801 turnover. During their theses, Dr. Joan Romaní-Aumedes found that RTP801 can be ubiquitinated by parkin for proteasomal degradation.  Dr. Mercè Canal also found NEDD4 is able to ubiquitinate RTP801 to mediate its lysosomal degradation.

References:

1. Ryu EJ, Angelastro JM, Greene LA. Analysis of gene expression changes in a cellular model of Parkinson disease. Neurobiol Dis. 2005 Feb;18(1):54-74.PMID: 15649696

2. Malagelada C, Ryu EJ, Biswas SC, Jackson-Lewis V, Greene LA. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci. 2006;26(39):9996-10005.

3. Malagelada C, Zong HJ, Greene LA. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci. 2008;28(53).

4. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci. 2010;30(3):1166-1175.

5. Romaní-Aumedes J, Canal M, Martín-Flores N, Pérez-Fernández V, Wewering S, Fernández-Santiago R, Ezquerra M, Pont-Sunyer C, Lafuente A, Alberch J, Luebbert H, Tolosa E, Greene LA, Malagelada C. Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease. Cell Death and Disease (2014) 5, e1364;

6. Canal M, Martín-Flores N, Pérez-Sisqués L, Romaní-Aumedes J, Atlas B., Man HY, Kawabe H, Alberch J, Malagelada C. Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease. (Oncotarget 2016, August 2; 7(37):58813-58831).


mTOR signaling modulation of Levodopa-induced dyskinesia

L-DOPA-induced dyskinesia (LID) is the major invalidating adverse effect of chronic administration of L-DOPA, which is the only dopamine (DA) substitutive treatment currently available in PD. Susceptibility to LID is largely variable in patients, and its modulating factors are not yet elucidated. Currently, we are investigating which discriminatory single nucleotide polymorphisms (SNPs) in the genes of the mTOR pathway are associated with LID in subjects diagnosed with PD.  Moreover, we found that SNPs in the mTOR pathway and in the SNCA gene interacted to modulate the risk of age at onset for PD.

This is a project funded in 2014 by the Michael J. Fox Foundation and some of the results have been patented. This project is being developed  by teaming up with neurologist Dr. Maria Josep Martí and Dr. Eduard Tolosa (Hospital Clínic) and the geneticists Dr. Mario Ezquerra and Dr. Rubén Fernández-Santiago (IDIBAPS).

References: 

1. Martín-Flores N, Fernández-Santiago R, Antonelli F, Cerquera C, Moreno V, Martí MJ, Ezquerra M & Malagelada C. mTOR pathway-based discovery of genetic susceptibility to L-DOPA-induced dyskinesia in Parkinson's disease patients. Mol Neurobiol, 2018, doi: 10.1007/s12035-018-1219-1.

2. Fernández-Santiago R, Martín-Flores N, Antonelli F, Cerquera C, Moreno V, Bandres-Ciga S, Manduchi E, Tolosa E, Singleton AB, Moore JH; International Parkinson's Disease Genomics Consortium, Martí MJ, Ezquerra M, Malagelada C. SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.  Mov Disord. 2019 Sep;34(9):1333-1344. doi: 10.1002/mds.27770. Epub 2019 Jun 24.



PUBLICATIONS FROM THE LAB:


  • CD300f immune receptor contributes to healthy aging by regulating inflammaging, metabolism, and cognitive decline.Evans F, Alí-Ruiz D, Rego N, Negro-Demontel ML, Lago N, Cawen FA, Pannunzio B, Sanchez-Molina P, Reyes L, Paolino A, Rodríguez-Duarte J, Pérez-Torrado V, Chicote-González A, Quijano C, Marmisolle I, Mulet AP, Schlapp G, Meikle MN, Bresque M, Crispo M, Savio E, Malagelada C, Escande C, Peluffo H.Cell Rep. 2023 Oct 20;42(10):113269. doi: 10.1016/j.celrep.2023.113269. Online ahead of print.PMID: 37864797 Free article.
  • Neuron-derived extracellular vesicles contain synaptic proteins, promote spine formation, activate TrkB-mediated signalling and preserve neuronal complexity.Solana-Balaguer J, Campoy-Campos G, Martín-Flores N, Pérez-Sisqués L, Sitjà-Roqueta L, Kucukerden M, Gámez-Valero A, Coll-Manzano A, Martí E, Pérez-Navarro E, Alberch J, Soriano J, Masana M, Malagelada C.J Extracell Vesicles. 2023 Sep;12(9):e12355. doi: 10.1002/jev2.12355.PMID: 37743539 Free PMC article
  • Tcf20 deficiency is associated with increased liver fibrogenesis and alterations in mitochondrial metabolism in mice and humans.Córdoba-Jover B, Ribera J, Portolés I, Lecue E, Rodriguez-Vita J, Pérez-Sisqués L, Mannara F, Solsona-Vilarrasa E, García-Ruiz C, Fernández-Checa JC, Casals G, Rodríguez-Revenga L, Álvarez-Mora MI, Arteche-López A, Díaz de Bustamante A, Calvo R, Pujol A, Azkargorta M, Elortza F, Malagelada C, Pinyol R, Huguet-Pradell J, Melgar-Lesmes P, Jiménez W, Morales-Ruiz M.Liver Int. 2023 Aug;43(8):1822-1836. doi: 10.1111/liv.15640. Epub 2023 Jun 14.PMID: 37312667
  • STAT3 and REDD1: an unconventional story of gene repression.Garcia-Segura P, Malagelada C.FEBS J. 2023 Apr;290(7):1735-1739. doi: 10.1111/febs.16727. Epub 2023 Jan 30.PMID: 36715132
  • Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers.Garrido A, Pérez-Sisqués L, Simonet C, Campoy-Campos G, Solana-Balaguer J, Martín-Flores N, Fernández M, Soto M, Obiang D, Cámara A, Valldeoriola F, Muñoz E, Compta Y, Pérez-Navarro E, Alberch J, Tolosa E, Martí MJ, Ezquerra M, Malagelada C, Fernández-Santiago R.Ann Neurol. 2022 Nov;92(5):888-894. doi: 10.1002/ana.26469. Epub 2022 Sep 26.PMID: 35929078 Free PMC article.
  • Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.Garrido A, Santamaría E, Fernández-Irigoyen J, Soto M, Simonet C, Fernández M, Obiang D, Tolosa E, Martí MJ, Padmanabhan S, Malagelada C, Ezquerra M, Fernández-Santiago R.Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28927. Online ahead of print.PMID: 35049090
  • RTP801/REDD1 Is Involved in Neuroinflammation and Modulates Cognitive Dysfunction in Huntington's Disease.Pérez-Sisqués L, Solana-Balaguer J, Campoy-Campos G, Martín-Flores N, Sancho-Balsells A, Vives-Isern M, Soler-Palazón F, Garcia-Forn M, Masana M, Alberch J, Pérez-Navarro E, Giralt A, Malagelada C.Biomolecules. 2021 Dec 27;12(1):34. doi: 10.3390/biom12010034.PMID: 35053183
  • RTP801/REDD1 contributes to neuroinflammation severity and memory impairments in Alzheimer's disease.Pérez-Sisqués L, Sancho-Balsells A, Solana-Balaguer J, Campoy-Campos G, Vives-Isern M, Soler-Palazón F, Anglada-Huguet M, López-Toledano MÁ, Mandelkow EM, Alberch J, Giralt A, Malagelada C.Cell Death Dis. 2021 Jun 15;12(6):616. doi: 10.1038/s41419-021-03899-y.PMID: 34131105
  • R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils.Fan Y, Nirujogi RS, Garrido A, Ruiz-Martínez J, Bergareche-Yarza A, Mondragón-Rezola E, Vinagre-Aragón A, Croitoru I, Gorostidi Pagola A, Paternain Markinez L, Alcalay R, Hickman RA, Düring J, Gomes S, Pratuseviciute N, Padmanabhan S, Valldeoriola F, Pérez Sisqués L, Malagelada C, Ximelis T, Molina Porcel L, Martí MJ, Tolosa E, Alessi DR, Sammler EM.Acta Neuropathol. 2021 Sep;142(3):475-494. doi: 10.1007/s00401-021-02325-z. Epub 2021 Jun 14.PMID: 34125248
  • RTP801 regulates motor cortex synaptic transmission and learning.Pérez-Sisqués L, Martín-Flores N, Masana M, Solana-Balaguer J, Llobet A, Romaní-Aumedes J, Canal M, Campoy-Campos G, García-García E, Sánchez-Fernández N, Fernández-García S, Gilbert JP, Rodríguez MJ, Man HY, Feinstein E, Williamson DL, Soto D, Gasull X, Alberch J, Malagelada C.Exp Neurol. 2021 Aug;342:113755. doi: 10.1016/j.expneurol.2021.113755. Epub 2021 May 11.PMID: 33984337
  • Martín-Flores N, Pérez-Sisqués L, Creus-Muncunill J, Masana M, Ginés S, Alberch J, Pérez-Navarro E, Malagelada C. Synaptic RTP801 contributes to motor-learning dysfunction in Huntington's disease. Cell Death Dis. 2020 Jul 30;11(7):569. doi: 10.1038/s41419-020-02775-5.
  • Creus-Muncunill J, Badillos-Rodríguez R , Garcia-Forn M, Masana M, Garcia-Díaz Barriga G, Guisado-Corcoll A, Alberch J, Malagelada C, Delgado-García JM, Gruart A, Pérez-Navarro E. Increased translation as a novel pathogenic mechanism in Huntington's disease. Brain. 2019 Oct 1;142(10):3158-3175
  • Fernández-Santiago R, Martín-Flores N, Antonelli F, Cerquera C, Moreno V,  Bandres-Ciga S, Manduchi E, Tolosa E, Singleton A, Moore JH, The International Parkinson's Disease Genomics Consortium (IPDGC), Martí MJ, Ezquerra M & Malagelada C. SNCA and mTOR pathway SNPs interact to modulate the age-at-onset of Parkinson's disease. Movement Disorders 2019 Sep;34(9):1333-1344
  • Martín-Flores N, Fernández-Santiago R, Antonelli F, Cerquera C, Moreno V, Martí MJ, Ezquerra M & Malagelada C. mTOR pathway-based discovery of genetic susceptibility to L-DOPA-induced dyskinesia in Parkinson's disease patients. Mol. Neurobiol (2018), doi: 10.1007/s12035-018-1219-1.
  • Creus-Muncunill J, Rué L, Alcalá-Vida R, Badillos-Rodríguez R, Romaní-Aumedes J, Marco S, Alberch J, Perez-Otaño I, Malagelada C, Pérez-Navarro E. Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration. Mol Neurobiol. 2018 Oct;55(10):7728-7742.

  • Canal M, Martín-Flores N, Pérez-Sisqués L, Romaní-Aumedes J, Atlas B., Man HY, Kawabe H, Alberch J, Malagelada C. Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease. Oncotarget (2016, August 2); 7(37):58813-58831.
  • Martín-Flores N, Romaní-Aumedes J, Rué L, Canal M, Sander P, Straccia M, Allen N, Alberch J, Canals JM, Pérez-Navarro E, Malagelada C. RTP801 is involved in mutant huntingtin-induced cell death. Mol. Neurobiol (2015), doi: 10.1007/s12035-015-9166-6.
  • Canal M, Romaní-Aumedes J, Martín-Flores N, Pérez-Fernández V, Malagelada C. RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders. Front Cell. Neurosci (2014), doi 10.3389/fncel.2014.00313.
  • Romaní-Aumedes J, Canal M, Martín-Flores N, Pérez-Fernández V, Wewering S, Fernández-Santiago R, Ezquerra M, Pont-Sunyer C, Lafuente A, Alberch J, Luebbert H, Tolosa E, Greene LA, Malagelada C. Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease. Cell Death and Disease (2014) 5, e1364; doi:10.1038/cddis.2014.333.t.
UNIT OF BIOCHEMISTRY, Dept of Biomedicine, Casanova 143, 3rd floor, north wing, Faculty of Medicine, University of Barcelona 08036 Barcelona, Catalonia, Spain +34-934021919 
Powered by Webnode Cookies
Create your website for free!